|

GI-102 subcutaneous (SC) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • GI Innovation, Inc.1

Indications

  • Liver Disease1
  • Platinum-resistant Ovarian Cancer (PROC)1
  • Soft Tissue Sarcoma (STS)1
  • Renal Cell Carcinoma (RCC)1
  • Diabetes1

Scottsdale, Arizona1 trial

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Mayo Clinic in Arizona

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.